Talk:Autism spectrum

Endocannabinoids

• Endocannabinoid Signaling in Autism
• The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
• Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention
• The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.

Pharmacotherapy

• CBD: Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.

Endogenous dopamine

• Dopamine and the Development of Executive Dysfunction in Autism Spectrum Disorders
• A Dopamine Hypothesis of Autism Spectrum Disorder.
• Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD).

Endogenous melatonin

• Melatonin in Children with Autism Spectrum Disorders: How Does the Evidence Fit Together?
• Melatonin in autism spectrum disorders.
• Melatonin in autism spectrum disorders: a systematic review and meta-analysis.

"Opioid theory of autism - first proposed by Panksepp, confirmed by Reichelt and Shattock - which held that children with autism had many abnormal peptides (small pieces of partially broken down proteins) in their urine, including casomorphine and gliadomorphin... Autistic children studied had casomorphine and gliadomorphin unless they were on the diet. More importantly, he also found 2 other morphine-related compounds, dermorphin and deltorphin II, in the urine of these children. (Alan Friedman)"^[1]

Endogenous opioids

• Biologically active peptide-containing fractions in schizophrenia and childhood autism.
• Brain opioids and autism: an updated analysis of possible linkages.
• Opioid peptides and dipeptidyl peptidase in autism.
• μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.
• Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention.
• Opioid peptides and gastrointestinal symptoms in autism spectrum disorders.
• Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians.

• Meta-analysis: In 19 clinical trials, covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress, the effects of oxytocin administration were tested, with doses ranging from 15 IU to more than 7000 IU. However, of all disorders, only studies on autism spectrum disorder showed a significant combined effect size.^[2]

Endogenous serotonin

• Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study.
• Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia.

Pharmacotherapy

• LSD: Flashback to the 1960s: LSD in the treatment of autism.

Entacogens

• MDMA: MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
• MDMA: Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.

• Talk:Pharmaceutical
• Talk:Psychiatric diagnoses

• Autism spectrum (Wikipedia)